Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $15.80.

Several brokerages have recently issued reports on ZURA. Chardan Capital decreased their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Finally, Leerink Partners started coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target for the company.

Zura Bio Trading Up 3.3 %

Shares of NASDAQ ZURA opened at $1.55 on Thursday. Zura Bio has a 12 month low of $1.35 and a 12 month high of $6.35. The stock has a 50 day moving average of $2.07 and a 200-day moving average of $3.22.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Several hedge funds have recently bought and sold shares of ZURA. JPMorgan Chase & Co. lifted its stake in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after buying an additional 2,611,532 shares in the last quarter. Braidwell LP purchased a new stake in Zura Bio during the third quarter valued at approximately $10,040,000. Sphera Funds Management LTD. purchased a new stake in shares of Zura Bio in the third quarter worth $2,999,000. Geode Capital Management LLC increased its stake in shares of Zura Bio by 70.6% in the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after purchasing an additional 377,545 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Zura Bio in the fourth quarter worth $750,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.